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likelihood of suicide, absenteeism, and the hospitalisation rate. The reimburse-
ment of Seroquel XR® could generate annual budget savings of PLN 8.6 million (
2150 thousands Euro), if Seroquel XR® were used in 31% of quetiapine-treated
patients with schizophrenia. The maximum savings resulting from the reimburse-
ment of quetiapine prolonged release tablets (Seroquel XR®) could amount to PLN
27.6 million (6900 thousands Euro) per year. CONCLUSIONS: The reimbursement of
Seroquel XR® with the reimbursement limit at the level of the reimbursement limit
for normal tablets of quetiapine is profitable for the state budget – it will not only
bring budgetary savings, but also allow patients to return to active life, which is
crucial in the case of schizophrenia.
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OBJECTIVES: To estimate the economic consequences of replacing Seroquel (the
normal tablets of quetiapine) with Seroquel XR® in the treatment of bipolar disor-
der in Poland. METHODS: Based on the established model of the economic conse-
quences of bipolar disorder treatment, we calculated the cost of treating bipolar
disorder with quetiapine in Poland. Expenditures for the purchase of medicines,
hospital costs and the costs of lost productivity were highlighted. The analysis was
performed from a societal perspective, taking into account the Payer’s perspective,
in three–year time horizon. RESULTS: The use of Seroquel XR® will decrease hos-
pitalisation rate and length of hospitalisation, what will reduce direct costs of
bipolar disorder treatment by PLN 645 thousands (161 thousands Åuro). The use of
Seroquel XR® will increase the population of patients who comply with the recom-
mended treatment, which will reduce the likelihood of suicide, absenteeism, and
the disability pension. The budget savings related to indirect costs reduction are
estimated at PLN 15,3 million (3825 thousands Euro). Moreover, the reimursement
of Seroquel XR® would decrease the social transfers by PLN 157,6 thousands (39,4
thousands Euro) in comparison to current scenario. CONCLUSIONS: The reim-
bursement of Seroquel XR® with the reimbursement limit at the level of the reim-
bursement limit for normal tablets of quetiapine is profitable for the state budget –
it will not only bring budgetary savings, but also allow patients to return to active
life, which is crucial in the case of bipolar disorder.
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OBJECTIVES: Schizophrenia is a debilitating chronic psychiatric illness with a con-
siderable impact on the patient and the patient’s environment, in terms of mor-
bidity, mortality, human suffering and societal costs. Currently, little is known of
the exact cost of relapse in schizophrenia. Our objective is to estimate cost of
relapse based on resource utilization data collected alongside a clinical trial.
METHODS: “Constatre” is a multicenter, open-label, randomized, active-control,
long-term study comparing risperidone long acting injectable treatment with oral
quetiapine, conducted from October 2004 to November 2007 at 124 sites in 25 coun-
tries (ClinicalTrials.gov identifier: NCT00216476). Information regarding Medical
Resource Utilization (MRU) during the three months following relapse was col-
lected for a subset of patients. To estimate the associated relapse related costs,
average purchase power parity adjusted country resource unit costs (2010 Euro)
were applied. RESULTS: Detailed MRU data were available for 63 patients spread
across Europe. The overall mean MRU cost per patient in the three months follow-
ing the relapse was €7592, of which 79% was related to psychiatric hospitalisation.
68% of the relapsed patients were hospitalized, for on average 38.8 days, represent-
ing a total cost of €9117 (range €277 - €20,868) per hospitalised patient. 5% of the
patients were in day-clinic, on average for 41.3 days, representing a cost of €5829
per patient. The majority (60%) of the relapsed patients had outpatient visits, rep-
resenting a mean cost per patient of €1834, mainly to psychiatrists (57% of patients,
average  14.5 visits) and nurses (10% of patients, average  105.9 visits).
CONCLUSIONS:Costs related to relapse of schizophrenic patients are considerable,
and mainly driven by psychiatric hospitalisation. Antipsychotic treatment that
prevents or reduces relapse and psychiatric hospitalisation can have a major im-
pact on the total schizophrenia related treatment cost.
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OBJECTIVES: To compare the differences in health care costs between alcohol or
opioid-dependent patients who were treated with pharmacological (’Any Medica-
tion’) and non-pharmacological substances (’No Medication’). METHODS: A retro-
spective analysis was conducted using a large U.S. health plan claims database
from 2005 to 2009. Continuously eligible patients with at least one claim of alcohol/
opioid dependence during the identification period, and an alcohol/opioid use dis-
order diagnosis during the baseline period were included. Propensity score match-
ing (PSM) was applied to compare the risk-adjusted outcomes between the ’Any
Medication’ and ’No Medication’ cohorts. Baseline differences in age, gender, re-
gion, comorbidity scores, socioeconomic status, baseline health care utilization
and costs were controlled. RESULTS: During the pre-index period, for both alcohol
and opioid dependent patients, those in the ’Any Medication’ cohort had more
distinct psychiatric diagnoses, and were more likely to have Elixhauser Index
Scores of higher than 3, when compared to patients from the ’No Medication’
cohort. After adjusting baseline patient and clinical characteristics, 10,376 alcohol-
dependent patients were matched from each cohort. Patients who were treated
without pharmacological medication had more rehabilitation time, a higher detox-
ification cost burden ($1,350,000 per 1000 patients), and higher total health care
costs, compared to patients who were treated with pharmacological medication.
Similarly, there were 6,658 patients from each cohort matched for opioid-depen-
dent patients. Patients in the ’No Medication’ cohort incurred higher total health
care costs than patients in the ’Any Mediation’ cohort ($14,353,000 vs. $ 10,192,000
per 1000 patients) during the post-index period. CONCLUSIONS: After controlling
for confounders such as demographic factors, comorbid conditions and baseline
health care utilization, we showed that pharmacological medication treatments
were associated with lower health care costs than non-pharmacological substance
treatment for both alcohol and opioid-dependent patients.
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OBJECTIVES: Substance abuse (SA) represents a significant public health problem
that impacts tens of millions of persons in the US and imposes over $400 billion in
annual economic costs on a national basis in the form of lost productivity, prema-
ture death, criminal activity and use of medical care. The objective of this study
was to estimate the economic costs associated with drug and alcohol abuse for
Washington State in 2005.METHODS:We used standard cost of illness (COI) meth-
ods, relying on the prevalence approach, to estimate the costs of SA in six areas,
including mortality, morbidity, treatment costs, crime, and health care. We ob-
tained data for the analysis from various sources, including the Washington State
Health Department, the National Survey on Drug Use and Health, the State Depart-
ment of Corrections, and the Washington Association of County Sheriffs, and the
Washington State Department of Transportation. RESULTS: We estimated costs of
SA for 2005 for Washington State at $5.21 billion, $832 per non-institutionalized
person in the state. Alcohol abuse accounted for 56% of total costs. The per-capita,
inflation-adjusted costs increased by 47% from 1996. Categories accounting for the
greatest costs were mortality ($2.03 billion), crime ($1.09 billion), morbidity ($1.03
billion) and health care ($791 million). There were 3,224 deaths (7% of all deaths),
89,000 years of productive life lost, and 29,000 hospital discharges in 2005 in Wash-
ington associated with SA. CONCLUSIONS: SA imposes significant costs on society.
Its economic costs far outweigh the resources expanded to treat persons with SA.
For every $1 dollar the state collected in tax revenue for treatment from alcohol
sales in 2005, $20 in economic loss was incurred from alcohol abuse. Renewed
attention needs to be directed at finding more effective ways to reduce the eco-
nomic and human loss arising from SA.
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OBJECTIVES: This comprehensive review was conducted to report existing evi-
dence from published studies evaluating the economic burden of attention deficit
hyperactivity disorder (ADHD) in children and adolescents in Europe.METHODS:A
systematic search of electronic literature databases (EMBASE and MEDLINE), was
conducted from January 2001 to June 2011 to identify economic studies on ADHD in
children and adolescents in Europe. All economic studies in English language,
regardless of design and intervention were included. Eligibility of trials was as-
sessed by two reviewers with any discrepancy reconciled by a third, independent
reviewer. RESULTS: A total of 591 citations were retrieved out of which eight met
pre-defined inclusion criteria. Five studies were cost-analyses while three were
cost-effectiveness analyses. In Germany, the total direct costs for ADHD were €158
million in 2002 which increased to €287 million in 2006 with inpatient treatment
costs comprising approximately 40% of the total direct costs in 2006 (Wehmeier
2009). Other contributors to total direct costs included hospitalisations, special
health-care services, comorbidities, and physician visits (Ridder 2006). The total
projected costs of ADHD in Germany during 2012 are estimated to be €311 million
(Schlander 2007). The mean annual direct medical costs of ADHD patients with
psychiatric comorbidities were €5908 compared to €974 for ADHD alone in the The
Netherlands (Roijen 2007). The cost-effectiveness studies retrieved primarily fo-
cused on atomoxetine (ATX) and methylphenidate (MPH). ATX was found to be
more cost-effective than MPH in the UK (ICER of £15 224 per QALY gained) (Cottrell
2008) as well as in Spain (ICER of €34 308 per QALY gained) (Hong 2009).
CONCLUSIONS:ADHD is associated with substantial fiscal burden in Europe. Since
2002, a trend of increase in direct costs has been observed which may be due to
increasing demand for healthcare services, and presence of comorbidities.
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OBJECTIVES: There has been a growing concern about the economic burden of
work incapacity due to mental health problems; meanwhile studies examining the
employer’s perspective are still scarce. This study aims to propose a rationale to
estimate the burden of mental health problems in Brazilian corporations.
METHODS:Data from an observational study investigating absenteeism due to sick
leaves in a Brazilian bank were used to build a costing estimation model (total
number of employees, average number of sick days per employee, and proportion
of sick days due to mental ill health). These data were combined with average wage
and turnover rate national statistics and published data on presenteeism due to
mental health problems. RESULTS: Based on n7499 workers, 3.36 annual sick
days per employee, a proportion of sick days attributable to mental health disor-
ders of 15.58%, and a mean daily wage of 51.33BRL, the costing model projected
annual costs due to absenteeism of 201,534BRL. If presenteeism is included in the
costing estimation, using a previously published presenteeism/absenteeism ratio
of 4.0 (for depressed workers), costs due to presenteeism would represent
806,138BRL per year. There is a lack of Brazilian observational studies assessing
turnover rates and associated costs. National rates according to economic sector
were employed to estimate the impact of turnover of mental ill workers (Service
Industry4.15% in 2010) and a turnover cost of 3 times the average monthly cost
per employee were used as a proxy. Turnover costs would incur in additional
115,500BRL per year. The annual economic burden of mental health disorders un-
der the employers perspective was estimated in 1,123,173BRL. CONCLUSIONS: The
cost of mental ill health to employers, particularly the cost of productivity losses
due to lower performance of employees at work (presenteeism), can represent a
significant burden for companies and society.
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OBJECTIVES:Mental illnesses in Pakistan are at rise. Decade long terrorism, suicide
bombing, recent floods, political uncertainty and transition to market economy are
some of the key factors that are contributing to increasing mental illnesses in the
country. This study emphasizes the importance of economic consequences of
mental illness in Pakistan and provides estimates of cost on mental illness in the
country. METHODS: Aga Khan University Hospital patient records of psychiatry
clinics inpatient (N727) and outpatient (N1458) data for the year 2005-06 were
classified into ten ICD-10 classification. For each category of mental illness the
direct cost included consultation fee, diagnostics, bed charges, laboratory charges
medication and procedure. The indirect costs on travel and productivity losses are
being estimated drawing a stratified random sample for both inpatient and day
care dataset. RESULTS: Mental illnesses categories 2(Schizophrenia (N227) and
3(mood/depressive disorder (N415) accounted for 82% of burden of mental ill-
nesses in inpatient care. While in day care 2(Schizophrenia 3(mood/depressive
disorder and 4(Panic/OCD) accounted for 75 % of the burden of mental illnesses in
Pakistan. Mean cost for all categories in inpatient care is Pak Rs. 21701 per treat-
ment episode. Illnesses category 8 (anorexia) was the most costly (MeanRs.71687)
and category 1(dementia and other organic disorders were relatively less expensive
to treat (MeanPak Rs.1183). CONCLUSIONS: Initial findings suggest the economic
burden of mental illnesses is alarmingly high and its treatment is unaffordable by
many families in the country. This might result in denied or delayed care. Using
country level available data on burden of mental illness the economic impact of
mental illnesses in Pakistan will be estimated. We will also explain socio-economic
determinates of mental illnesses.
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OBJECTIVES: There is little data describing current practice in the clinical manage-
ment of patients with psychosis and co-occurring substance use and the associated
costs. In the UK, standard psychiatric care is based on the care programme ap-
proach and includes community and hospital-based treatment. Inpatient psychi-
atric treatment is the key cost driver of psychiatric care. This study aimed to de-
scribe practice-based patient-level costs of inpatient psychiatric treatment for NHS
patients with psychosis and co-occurring substance use. METHODS: Resource use
data of inpatient psychiatric treatment were collected from the medical records of
327 patients recruited in the MIDAS trial, a randomised controlled trial of an ex-
perimental intervention programme (integrated motivational interviewing and
cognitive-behaviour therapy, MiCBT) plus standard care or standard care alone.
Using the hospital perspective, data were collected from trial entry until end of
2-year trial follow-up (between 2004 to 2009). Unit costs were assigned, based on
NHS Reference Costs 2008/09 and PSSRU 2009. Data were analysed using descrip-
tive statistics and variations around the costs were obtained. RESULTS: Of the 327
patients, 95 patients (29%) experienced at least one episode of hospitalisation, with
a mean of 85 inpatient days (95% CI: 65 – 105, median 42, range 2 - 568) per hospi-
talised patient. Total cost for these 95 patients was £2.43million (UK £2008/09) over
8,108 inpatient days. Mean cost per hospitalised patient was £25,547 (95% CI:
£18,453 – £32,640, median £12,180, range £580 – £273,208). Cost components com-
prised: acute psychiatric admission (total 6,428 days, £1.86million), psychiatric re-
habilitation admission (total 621 days, £165,186), psychiatric long-stay admission
(total 434 days, £91,574), psychiatric ICU admission (total 57 days, £32,832) and
psychiatric forensic medium secure unit admission (568 days, £273,208).
CONCLUSIONS: This study provided practice-based data describing patient-level
costs associated with standard NHS care of inpatient psychiatric treatment for
patients with psychosis and co-occurring substance use.
PMH26
DIRECT COST OF SCHIZOPHRENIA IN QUEBEC, CANADA: AN INCIDENCE-BASED
MICROSIMULATION MONTE-CARLO MARKOV MODEL
Dragomir A1, Tarride JE2, Angers JF3, Joober R4, Rouleau G3, Perreault S5
1University of Montreal, Montreal, QC, Canada, 2McMaster University, Hamilton, ON, Canada,
3Université de Montréal, Montreal, QC, Canada, 4Institut Douglas, Montreal, QC, Canada,
5Université de Montréal, Montréal, QC, Canada
OBJECTIVES: Pharmacological strategies for schizophrenia have received increas-
ing attention due to the development of new and costly drug therapies. To estimate
the direct healthcare and non-healthcare cost of schizophrenia and to simulate
cost reductions potentially obtained with a new pharmacogenomics treatment, in
a cohort of patients newly diagnosed with schizophrenia, over the first 5 years
following their diagnosis. METHODS: A microsimulation Monte-Carlo Markov
model was used. Six discrete disorder states defined the Markov model: 1): first
episode (FE); 2) low dependency state (LDS); 3) high dependency state (HDS); 4)
Stable state (Stable); 5) Well state (Well); and 6) Death state (Death). Costs and
individual probabilities of transition were estimated from the Régie de l’assurance
maladie du Québec and Med-Echo databases. RESULTS: A total of 14,320 individu-
als were identified in the study cohort as newly diagnosed patients with schizo-
phrenia. Over the first 5 years following diagnosis the mean cost per person was
estimated at $36,701 (95%CI: 36,264 to 37,138). The direct health care cost accounted
for 56.2% of the total cost, welfare assistance for 34.6% and long term care facilities
for 9.2%. On the direct health care cost, hospitalisation cost accounted for 64.6%,
medical cost for 11.4% and drug-related cost for 24%. In the case where a new
pharmacogenomic treatment with 20% increase of effectiveness will be available,
the direct healthcare and non-health care costs can be reduced up to 14.2%.
CONCLUSIONS: This model is the first Canadian model incorporating transition
probabilities adjusted for individual risk-factor profiles and costs using real-life
data. Our results indicate that a new pharmacogenomics treatment could possibly
reduce hospitalization and long-term care facility costs while potentially enabling
patients to return to active employment that would in turn contribute to the re-
duction of the welfare assistance cost.
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OBJECTIVES: People addicted to opioids contribute a significant burden to society,
both in terms of quality of life (QoL) and economic consequences. Untreated users
are more likely to be out of work, commit crimes and require healthcare resources.
Treating patients has been demonstrated to reduce these factors. However, some
users receiving formal care continue to misuse that treatment, leading to other
significant consequences for society. This study evaluated the potential impact of
a novel formulation (buprenorphine/naloxone; suboxone), aimed at mitigating
misuse and diversion. Increasing the currently limited number of treatments avail-
able will likely increase the number of people in treatment. The objective was to
assess cost-effectiveness of two approaches to managing opioid users, buprenor-
phine/naloxone and methadone, and, further, to compare the use of any treatment
against no treatment. METHODS: A cost-effectiveness model was built, incorpo-
rating the costs and benefits associated with each treatment. Healthcare unit cost
data were taken from published data and databases, including NHS Reference
Costs 2009-2010 and PSSRU Unit Costs of Health and Social Care 2010. Crime costs
were taken from Home Office publications. Crime and hospitalisation rates, by
treatment, were taken from an observational study of 109 patients in Scotland.
Health related QoL figures, by treatment, were taken from an SF-36 questionnaire
study. RESULTS: Over 6 months, it was estimated that savings associated with
reduced crime (buprenorphine/naloxone versus methadone) were £2129, and sav-
ings from reduced health care visits were £1409. Based on a combination of mor-
tality and QoL improvements, patients on buprenorphine/naloxone were shown to
gain 0.087 QALYs compared to those receiving methadone. CONCLUSIONS: The
model showed that the cost implications of crime, hospitalisation and misuse and
diversion were key drivers of the results. Use of buprenorphine/naloxone resulted
in a saving of £3538 due to reduced crime and hospitalisations, whilst providing a
benefit to QoL.
PMH29
COST EFFECTIVENESS OF EXTENDED RELEASE QUETIAPINE FUMARATE
(QUETIAPINE XR) MONOTHERAPY IN TURKEY IN PATIENTS WITH MAJOR
DEPRESSIVE DISORDER (MDD) WHO HAVE FAILED PREVIOUS ANTIDEPRESSANT
THERAPY
Aydemir O1, Dilbaz N2, Malhan S3
1Adnan Menderes University, Manisa, Turkey, 2Ankara Numune Research & Training Hospital,
Ankara, Turkey, 3Baskent University, Ankara, Turkey
OBJECTIVES: The objective of this exploratory analysis was to assess the cost-
effectiveness of quetiapineXR as monotherapy compared to other key drug treat-
ments in MDD patients, who have failed on previous therapy.METHODS:A Markov
Model with one week cycles was used to assess the cost effectiveness of quetiap-
ineXR treatment over 52 weeks. Key outcomes were: response rates, costs and
Incremental Cost-Effectiveness Ratios (ICERs) for second line monotherapy. The
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